PMAIP1 is altered in 0.47% of all cancers with colon adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, breast invasive ductal carcinoma, and pancreatic adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PMAIP1 are PMAIP1 Loss (0.32%), PMAIP1 Amplification (0.06%), PMAIP1 X20_splice (0.01%), PMAIP1 L43* (0.01%), and PMAIP1 E20* (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.